Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/- mice

Neoplasia

Volumn 10, Issue 8, 2008, Pages 866-872

  Hollander, Mary Christine ^a   Balogh, Andria R ^a   Liwanag, Jaminelli ^a   Han, Wei ^a   Linnoila, Ritva Ilona ^a   Anver, Miriam R ^b   Dennis, Phillip A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CARCINOGEN; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CLASSIFICATION; CANCER SIZE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE SEVERITY; GENE DELETION; GENE MUTATION; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG CARCINOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOBACCO;

EID: 48249085827     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08406     Document Type: Article

References (29)

1. Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD, Veenstra TD, Issaq HJ, Linnoila RI, and Dennis PA (2007). Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res 13, 2281-2289.
2. Sansal I and Sellers WR (2004). The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22, 2954-2963.
3. Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK, and Kelsey KT (2005). PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 36, 768-776.
4. Brognard J, Clark AS, Ni Y, and Dennis PA (2001). Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61, 3986-3997.
5. Hecht SS, Chen CB, Hirota N, Ornaf RM, Tso TC, and Hoffmann D (1978). Tobacco-specific nitrosamines: formation from nicotine in vitro and during tobacco curing and carcinogenicity in strain A mice. J Natl Cancer Inst 60, 819-824.
6. Cantley LC and Neel BG (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96, 4240-4245.
7. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, Harris C, Belinsky S, and Dennis PA (2003). Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 111, 81-90.
8. Yanagi S, Kishimoto H, Kawahara K, Sasaki T, Sasaki M, Nishio M, Yajima N, Hamada K, Horie Y, Kubo H, et al. (2007). Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. J Clin Invest 117, 2929-2940.
9. Iwanaga K, Yang Y, Raso MG, Ma L, Hanna AE, Thilaganathan N, Moghaddam S, Evans CM, Li H, Cai WW, et al. (2008). Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res 68, 1119-1127.
10. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, and Parsons R (1999). Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96, 1563-1568.
11. tm1Rps PCR Protocol. Available at: http://mouse.ncifcrf.gov/ protocols.asp?ID=01XH3&p_allele=Pten%3Ctm1Rps%3E&prot_no=1.
12. Mouse Genome Informatics, Molecular Probes and Clones. Available at: http://www.informatics.jax.org/searches/probe.cgi?803644.
13. Hollander MC, Philburn RT, Patterson AD, Velasco-Miguel S, Friedberg EC, Linnoila RI, and Fornace AJ Jr (2005). Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis. Proc Natl Acad Sci USA 102, 13200-13205.
14. Linder CC (2006). Genetic variables that influence phenotype. ILAR J 47, 132-140.
15. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, and Mak TW (2000). High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res 60, 3605-3611.
16. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, et al. (1998). High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 8, 1169-1178.
17. You MJ, Castrillon DH, Bastian BC, O'Hagan RC, Bosenberg MW, Parsons R, Chin L, and DePinho RA (2002). Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci USA 99, 1455-1460.
18. Ryan J, Barker PE, Nesbitt MN, and Ruddle FH (1987). KRAS2 as a genetic marker for lung tumor susceptibility in inbred mice. J Natl Cancer Inst 79, 1351-1357.
19. Lin L, Festing MF, Devereux TR, Crist KA, Christiansen SC, Wang Y, Yang A, Svenson K, Paigen B, Malkinson AM, et al. (1998). Additional evidence that the K-ras protooncogene is a candidate for the major mouse pulmonary adenoma susceptibility (Pas-1) gene. Exp Lung Res 24, 481-497.
20. Li Y, Podsypanina K, Liu X, Crane A, Tan LK, Parsons R, and Varmus HE (2001). Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol Biol 2, 2.
21. Virmani AK and Gazdar AF (2003). Tumor suppressor genes in lung cancer. Methods Mol Biol 222, 97-115.
22. Belinsky SA, Devereux TR, Maronpot RR, Stoner GD, and Anderson MW (1989). Relationship between the formation of promutagenic adducts and the activation of the K-ras protooncogene in lung tumors from A/J mice treated with nitrosamines. Cancer Res 49, 5305-5311.
23. 6-methylguanine DNA adduct levels and Ki-ras activation in lung tumors from resistant and susceptible mouse strains. Mol Carcinog 8, 177-185.
24. Cully M, You H, Levine AJ, and Mak TW (2006). Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6, 184-192.
25. Lopiccolo J, Ballas MS, and Dennis PA (2007). PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development. Crit Rev Oncol Hematol 63, 203-214.
26. Tang JM, He QY, Guo RX, and Chang XJ (2006). Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51, 181-191.
27. Pan YH, Nuzum EO, Hanson LA, and Beer DG (1990). Ki-ras activation and expression in transformed mouse lung cell lines. Mol Carcinog 3, 279-286.
28. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, Nye E, Stamp G, Alitalo K, and Downward J (2007). Binding of ras to phosphoinositide 3-kinase p110α is required for ras-driven tumorigenesis in mice. Cell 129, 957-968.
29. Belinsky SA, Devereux TR, Foley JF, Maronpot RR, and Anderson MW (1992). Role of the alveolar type II cell in the development and progression of pulmonary tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the A/J mouse. Cancer Res 52, 3164-3173.